
    
      Patients who are deemed eligible will be enrolled and undergo a two stage transplant process
      followed by neurological assessments every 6 months for the following 5 years assessing EDSS,
      visual metrics, MRI, AQP-4 antibodies, MSFC and SF36.
    
  